| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 01/12/2010 | US7645595 Culturing epidermal keratinocytes on collagen gel layer containing human fibroblasts, exposing to air, and culture contains matrix metalloproteinase inhibitor such as N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride |
| 01/12/2010 | CA2483678C 6-11 bicyclic ketolide derivatives |
| 01/12/2010 | CA2468412C 17.alpha.-alkyl-17.beta.-oxy-estratrienes and intermediates for their production, use of the 17.alpha.-alkyl-17.beta.-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations |
| 01/12/2010 | CA2461946C Combinations for the treatment of immunoinflammatory disorders |
| 01/12/2010 | CA2438143C Modified proteins, designer toxins, and methods of making thereof |
| 01/12/2010 | CA2403514C 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 01/07/2010 | WO2010002244A1 Nutritional composition for infants delivered via caesarean section |
| 01/07/2010 | WO2010002241A1 Nutritional composition for infants delivered via caesarean section |
| 01/07/2010 | WO2010001990A1 Tetracyclic compound |
| 01/07/2010 | WO2010001933A1 Histone modification inhibitor specific to target gene |
| 01/07/2010 | WO2010001926A1 Water-containing composition |
| 01/07/2010 | WO2010001258A2 Inhibition of tumour growth and metastases |
| 01/07/2010 | WO2010000906A1 Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers |
| 01/07/2010 | WO2010000905A1 Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers |
| 01/07/2010 | WO2010000851A2 Methods for modulating angiogenesis via dystrophin dp71 |
| 01/07/2010 | WO2010000686A2 Composition for topical use |
| 01/07/2010 | WO2010000580A2 Use of rooibos or rooibos extracts with prebiotics for skin and hair |
| 01/07/2010 | WO2010000579A2 Use of rooibos or rooibos extracts for skin and hair |
| 01/07/2010 | WO2010000578A2 Use of honeybush or honeybush extracts with prebiotics for skin and hair |
| 01/07/2010 | WO2010000577A2 Use of honeybush or honeybush extracts for skin and hair |
| 01/07/2010 | WO2010000396A1 Salts comprising a pyrimidinecarboxylic acid derivative for cosmetic use |
| 01/07/2010 | WO2009129336A3 Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections |
| 01/07/2010 | WO2007045116A8 Treatment and prevention of benign pigmented moles (naevi) using artemisinine and the derivatives thereof |
| 01/07/2010 | US20100004338 Topical gel composition comprising azelaic acid |
| 01/07/2010 | US20100004335 Oral preparation for preventing or improving skin dryness |
| 01/07/2010 | US20100004311 Excitatory amino acid inhibitors for treating sensitive skins |
| 01/07/2010 | US20100004296 Waterborne topical compositions for the delivery of azelaic acid |
| 01/07/2010 | US20100004261 Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| 01/07/2010 | US20100004258 Novel Heterocyclic NF-kB Inhibitors |
| 01/07/2010 | US20100003353 Control of Blood Vessel Physiology to Treat Skin Disorders |
| 01/07/2010 | US20100003340 Cosmetic compositions for the treatment of skin and methods thereof |
| 01/07/2010 | US20100003315 Method and Composition for the Treatment of Skin Conditions |
| 01/07/2010 | US20100003314 Method and composition for the treatment of skin conditions |
| 01/07/2010 | US20100003249 Polypeptide constructs for topical administration |
| 01/07/2010 | US20100003248 Polypeptide constructs for rectal and/or vaginal administration |
| 01/07/2010 | US20100003237 In vivo temporal control of activatable matrix-degrading enzymes |
| 01/07/2010 | US20100003236 Use of c-glycoside derivatives as pro-desquamating active agents |
| 01/07/2010 | US20100003233 Compositions and methods for treatment of microbial infections |
| 01/07/2010 | US20100003210 External skin agent comprising modified clay for preventing inflammation |
| 01/07/2010 | DE202009013734U1 Mineralpulvermischung Mineral powder mixture |
| 01/07/2010 | CA2633585A1 Treatments for any and all mental/brain neuron/spinal cord illness |
| 01/06/2010 | EP2141148A1 Indole derivative having cpla2 inhibitory activity, use of the same and method for producing the same |
| 01/06/2010 | EP2140881A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 01/06/2010 | EP2140872A2 Composition for the treatment of skin conditions comprising sea water with additional magnesium |
| 01/06/2010 | EP2139862A1 Cosmetic preparations designed to reduce unsightly cellulite |
| 01/06/2010 | EP2139474A2 Transcription factor modulating compounds and methods of use thereof |
| 01/06/2010 | EP2139453A1 Polyaphron topical composition with vitamin d |
| 01/06/2010 | EP2139447A2 Gm-csf cosmeceutical compositions and methods of use thereof |
| 01/06/2010 | EP2139331A1 Compositions and methods relating to novel compounds and targets thereof |
| 01/06/2010 | EP1575938B1 Compounds having selective inhibiting effect at gsk3 |
| 01/06/2010 | EP1005361B1 USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY |
| 01/06/2010 | EP0963197B1 Guanylhydrazones useful for treating diseases associated with t cell activation |
| 01/06/2010 | CN100577681C Compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/06/2010 | CN100577181C Extraction of herbs by heating alcohol |
| 01/06/2010 | CN100577180C Application of gambogicacid in preparing medication for restraining angiogenesis |
| 01/06/2010 | CN100577170C Application of pyrazolopyrimidine Src family tyrosine kinase inhibitor in preparing medicament for curing myocardial infarction |
| 01/06/2010 | CN100577168C Cream for treating alopecia and preparation method thereof |
| 01/06/2010 | CN100577167C Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating disease related to dysfunction of peripheral benzodiazepin receptors |
| 01/06/2010 | CN100577144C Topical formulation for prevention and treatment of acne |
| 01/05/2010 | US7642903 Trailer tire alert system |
| 01/05/2010 | US7642351 2,4-Pyrimidinediamine compounds and their uses |
| 01/05/2010 | US7642276 N-[4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide; rheumatoid arthritis |
| 01/05/2010 | US7642243 Administering C-type natriuretic peptide, guanyl cyclase (GC-B)-activating peptide |
| 01/05/2010 | CA2545999C 1,2-di(cyclic)substituted benzene compounds |
| 01/05/2010 | CA2473503C Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 01/05/2010 | CA2465723C Process for reacting alkaloids and use of the reaction products in the preparation of medicaments |
| 01/05/2010 | CA2426467C Composition comprising 8-prenylnaringenin for treatment of skin |
| 01/05/2010 | CA2426457C Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 01/05/2010 | CA2318192C .beta.2-adrenergic receptor agonists |
| 01/05/2010 | CA2182810C Bacteriocin from micrococcus varians |
| 12/31/2009 | US20090326248 for treatment of insulin-like growth factor-1 receptor (IGF-1R) dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly; preferred compound is picropodophyllin |
| 12/31/2009 | US20090326052 Promoters exhibiting endothelial cell specificity and methods of using same |
| 12/31/2009 | US20090326038 Method for treating a immunology-related disease |
| 12/31/2009 | US20090326026 Tricyclic Compounds Useful as Angiotensin II Agonists |
| 12/31/2009 | US20090326003 Pyrazolo (3, 4-b) pyridine derivatives as pde4 inhibitors |
| 12/31/2009 | US20090325988 Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof |
| 12/31/2009 | US20090325983 New purine derivatives |
| 12/31/2009 | US20090325982 Phosphodiesterase 4 inhibitors |
| 12/31/2009 | US20090325962 Tyrosine derivative |
| 12/31/2009 | US20090325898 Skin material for external use and antiprutiric agent for external use and wrinkle-instrument using the same |
| 12/31/2009 | US20090325871 Role of the Mk2 Pathway in Wound Repair |
| 12/31/2009 | US20090325861 Dry wound dressing and drug delivery system |
| 12/31/2009 | US20090325289 Process for the multiplication of stem cells |
| 12/31/2009 | US20090324727 Nanoemulsion |
| 12/31/2009 | US20090324719 Extracellular matrix composition |
| 12/31/2009 | US20090324713 Spray-on, non-woven fabric system and multilayer wound coverings |
| 12/31/2009 | US20090324705 Phytonutrient compositions for topical use |
| 12/31/2009 | US20090324695 Biocompatible polymer ceramic composite matrices |
| 12/31/2009 | US20090324599 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity |
| 12/31/2009 | US20090324598 Method for the treatment of inflammatory disorders |
| 12/31/2009 | US20090324578 Composition and Method to Treat Wounds |
| 12/31/2009 | US20090324570 Photostabilization of Retinoids with Alkoxycrylene Compounds |
| 12/31/2009 | US20090324545 Polymorphic forms of (s)-1-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzyl carbamate |
| 12/31/2009 | US20090324520 Personal-care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents |
| 12/31/2009 | US20090324506 Sprayable skin protectant formulation and method of use |
| 12/31/2009 | DE202008011216U1 Dermatologische Salbe Dermatological ointment |
| 12/31/2009 | CA2724607A1 Method and composition for skin inflammation and discoloration |
| 12/30/2009 | WO2009158248A2 Method and compositions for improving skin and body appearance |
| 12/30/2009 | WO2009158144A1 Method and composition for dermatoses |
| 12/30/2009 | WO2009157858A1 Use of cyclolignans for the treatment of a hyperactive immune system |